<DOC>
	<DOCNO>NCT00044915</DOCNO>
	<brief_summary>The purpose trial evaluate Repinotan HCl patient acute ischemic stroke . At study entry patient randomize Repinotan HCl placebo 1:1 ratio . The total treatment period wil 72 hour .</brief_summary>
	<brief_title>Repinotan Patients With Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Acute ischemic stroke hemispheric localization ( exclude brainstem cerebellum ) , suspect thromboembolic origin . Males female age 18 year . National Institute Health Stroke Scale ( NIHSS ) total score 8 23 motor deficit &gt; /= 2 ( either one arm leg ) level consciousness &lt; 2 least one following : Visual field deficit , neglect , aphasia . If patient receives tPA , NIHSS must perform prior receive study drug infusion tPA initiate . Signed informed consent patient legally authorize representative CT scan evidence : Clearly define area hypodensity indicate infarction &gt; 1/3 MCA territory evidence significant mass effect shift midline major area sulcal effacement associate loss cortical definition ( greywhite distinction ) . Minor early CT change common MCA stroke patient early subtle change eligible . A primary intracerebral haemorrhage find consistent acute ischemic stroke cause presenting symptom . Clinical evidence acute stroke due lacunar infarct ( pure motor hemiplegia ; pure sensory deficit , ataxia/clumsy hand syndrome ) Neurological ( present stroke ) psychiatric condition may affect patient 's functional status and/or may interfere patient 's assessment Clinically relevant preexist neurological deficit ( Historical Rankin score &gt; /= 2 regardless cause ) Generalized seizures develop since onset stroke symptom Systolic blood pressure &gt; 210 &lt; 110 mmHg ( confirm three reading prior randomization ) Diastolic blood pressure &gt; 110 &lt; 60 mmHg ( confirm three reading prior randomization ) Myocardial infarction within 3 month , unstable angina within 35 day prior start infusion , unstable supraventricular and/or ventricular arrhythmia , severe conduction defect ( AV block grade 2 3 ) , complete leave right Bundle Branch Block , bradycardia ( heart rate [ HR ] le 50 bpm ) , uncompensated heart failure History myocarditis , cardiomyopathy aortic stenosis Patients know prolonged QTc interval ( inherit sporadic syndrome QTc prolongation QTc interval &gt; 450 msec male 470 msec female baseline ECG ) use Class IA Class III antiarrhythmic drug ( e.g. , quinidine , procainamide , amiodarone , sotalol ) Any patient require initiation new digoxin therapy exclude . Patients already digoxin therapy ( least 1 month stable dose ) time enrollment allow study . Electrolyte imbalance baseline . Should result available start study drug infusion , patient allow study provide corrective therapy abnormal electrolyte result implement immediately upon availability laboratory report . Any condition predispose electrolyte imbalance ( e.g. , chronic vomiting , anorexia nervosa , bulimia nervosa ) also exclude baseline . Participation research protocol investigation pharmaceutical agent innovative invasive procedure ( include intraarterial tPA ) within past 30 day Previously BRAINStudy treat repinotan Life expectancy le 6 month due comorbid condition Any know clinically significant medical disorder ( e.g. , cardiovascular , gastrointestinal , hepatic , renal , endocrine , major uncompensated metabolic disturbance , respiratory , immunological , hematological bleeding disorder , cancer , AIDS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Acute Ischemic Stroke Without Hemorrhage</keyword>
</DOC>